menu
    • menu

    Company profile for Qlaris Bio

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Qlaris Bio is a clinical stage biotechnology company founded with a singular focus: to develop novel, innovative therapies for serious and debilitating ophthalmic diseases. Qlaris Bio's lead program is QLS-101, a novel compound invented at Mayo Clinic and the University of Minnesota. With QLS-101, we are targeting a key, unaddressed component of intraocular pressure (IOP), Episcleral Venous Pressure (EVP) and outflow dista...
    Qlaris Bio is a clinical stage biotechnology company founded with a singular focus: to develop novel, innovative therapies for serious and debilitating ophthalmic diseases. Qlaris Bio's lead program is QLS-101, a novel compound invented at Mayo Clinic and the University of Minnesota. With QLS-101, we are targeting a key, unaddressed component of intraocular pressure (IOP), Episcleral Venous Pressure (EVP) and outflow distal to the Trabecular Meshwork, that remain wholly unaddressed today. In addition to its potential use alone or as an additive therapy in Primary Open Angle Glaucoma or in Ocular Hypertension

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Qlaris BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    55 William Street, Suite 250, Wellesley, MA 02481
    Telephone
    Telephone
    (781) 943-3519
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://qlaris.bio/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Qlaris Doses First Patient in Ph2 Nightingale Trial for Glaucoma
    Qlaris Doses First Patient in Ph2 Nightingale Trial for Glaucoma

    26 Aug 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-08-26/qlaris-bio-announces-first-patient-dosed-in-phase-ii-nightingale-clinical-trial-in-normal-tension-gl

    PHARMAWEB
    26 Aug 2025
    Share Share
    Qlaris Bio to Present Data on QLS-111 at 2025 Glaucoma Congress
    Qlaris Bio to Present Data on QLS-111 at 2025 Glaucoma Congress

    23 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250623858315/en/Qlaris-Bio-to-Present-New-Clinical-and-Preclinical-Data-on-QLS-111-at-2025-World-Glaucoma-Congress

    BUSINESSWIRE
    23 Jun 2025
    Share Share
    Qlaris Develops Combo Therapy of QLS-111 With Latanoprost
    Qlaris Develops Combo Therapy of QLS-111 With Latanoprost

    11 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250611125298/en/Qlaris-Bio-Announces-Development-of-Fixed-Dose-Combination-Therapy-with-QLS111-and-Latanoprost-for-the-Treatment-of-Glaucoma

    BUSINESSWIRE
    11 Jun 2025
    Share Share
    Daré's royalty deal; Qlaris Bio raises $24M
    Daré's royalty deal; Qlaris Bio raises $24M

    30 Apr 2024

    // ENDPTS

    https://endpts.com/dares-royalty-deal-qlaris-bio-raises-24m/

    ENDPTS
    30 Apr 2024
    Share Share
    Qlaris Bio Reports Phase 2 Clinical Trial Results for QLS-101
    Qlaris Bio Reports Phase 2 Clinical Trial Results for QLS-101

    18 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220518005187/en

    BUSINESSWIRE
    18 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search